ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | ||
| Conference Date: | February 11-12, 2025 | |
| Format: | Company Presentation and one-on-one meetings | |
| Presentation Time: | Tuesday, February 11, 2025, 4:00 to 4:30 PM ET | |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/imab/2739496 | |
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.
Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1 617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.38 |
| Daily Change: | 0.22 5.17 |
| Daily Volume: | 975,067 |
| Market Cap: | US$357.260M |
July 17, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
